AC
SBBP

Aristides Capital’s Strongbridge Biopharma plc. SBBP Stock Holding History

Aristides Capital’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-35,517
Closed -$74K – 281
2019
Q4 		$74K Buy
+35,517
New +$68.1K 0.06% 209

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Aristides Capital's SBBP Position: Q1 2020 in Review

Aristides Capital sold out of Strongbridge Biopharma plc. (SBBP) in Q1 2020, closing a stake of 35,517 shares — an estimated $74K sold.

Aristides Capital first reported a position in SBBP in Q4 2019 and held it in 1 quarter. The position peaked at $74K in Q4 2019. 60 funds tracked by Wall St. Rank hold SBBP as of Q1 2020.

  • Aristides Capital reported no remaining Strongbridge Biopharma plc. position as of Q1 2020 after selling out during the quarter.
  • Aristides Capital sold 35,517 Strongbridge Biopharma plc. shares in Q1 2020, an estimated $74K.
  • Aristides Capital first reported a position in Strongbridge Biopharma plc. in Q4 2019 and held it in 1 quarter.
  • Aristides Capital's Strongbridge Biopharma plc. position peaked at $74K in Q4 2019.
  • 60 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q1 2020.

Based on Aristides Capital's 13F filing for Q1 2020, filed 15 May 2020.